{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T12:58:41Z","timestamp":1725886721263},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:00:00Z","timestamp":1436313600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13256-015-0634-4","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T19:33:31Z","timestamp":1436297611000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dupuytren\u2019s contractures associated with the BRAF inhibitor vemurafenib: a case report"],"prefix":"10.1186","volume":"9","author":[{"given":"Sze Wai","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Alberto","family":"Vorobiof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,8]]},"reference":[{"key":"634_CR1","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507\u201316.","journal-title":"N Engl J Med."},{"key":"634_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase, 3, randomised, open-label study. Lancet Oncol. 2014;15:323\u201332.","journal-title":"Lancet Oncol."},{"key":"634_CR3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","volume":"15","author":"J Larkin","year":"2014","unstructured":"Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15:436\u201344.","journal-title":"Lancet Oncol."},{"key":"634_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","volume":"18","author":"ME Lacouture","year":"2013","unstructured":"Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18:314\u201322.","journal-title":"Oncologist."},{"key":"634_CR5","first-page":"AB179","volume":"68","author":"LTM Bicknell","year":"2013","unstructured":"Bicknell LTM, Ciurea A, Diaz L, Hymes S. Dupuytren\u2019s contractures secondary to BRAF kinase inhibitor therapy. J Am Acad Dermatol. 2013;68:AB179.","journal-title":"J Am Acad Dermatol."},{"key":"634_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jbspin.2013.12.009","volume":"81","author":"V Sibaud","year":"2014","unstructured":"Sibaud V, Chevreau C. Abrupt development of Dupuytren\u2019s contractures with the BRAF inhibitor vemurafenib. Joint Bone Spine. 2014;81:373\u20134.","journal-title":"Joint Bone Spine."},{"key":"634_CR7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0749-0712(21)00439-X","volume":"15","author":"DC Ross","year":"1999","unstructured":"Ross DC. Epidemiology of Dupuytren\u2019s disease. Hand Clin. 1999;15:53\u201362.","journal-title":"Hand Clin."},{"key":"634_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11552-007-9076-9","volume":"3","author":"SG Anthony","year":"2008","unstructured":"Anthony SG, Lozano-Calderon SA, Simmons BP, Jupiter JB. Gender ratio of Dupuytren\u2019s disease in the modern U.S. population. Hand (N Y). 2008;3:87\u201390.","journal-title":"Hand (N Y)."},{"key":"634_CR9","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.4049\/jimmunol.1302616","volume":"192","author":"JS Wilmott","year":"2014","unstructured":"Wilmott JS, Haydu LE, Am M, Lum T, Hyman J, Thompson JF, et al. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. J Immunol. 2014;192:2505\u201313.","journal-title":"J Immunol."},{"key":"634_CR10","doi-asserted-by":"publisher","first-page":"E928","DOI":"10.1073\/pnas.1301100110","volume":"110","author":"LS Verjee","year":"2013","unstructured":"Verjee LS, Verhoekx JS, Chan JK, Krausgruber T, Nicolaidou V, Izadi D, et al. Unraveling the signaling pathways promoting fibrosis in Dupuytren\u2019s disease reveals TNF as a therapeutic target. Proc Natl Acad Sci U S A. 2013;110:E928\u201337.","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-015-0634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-015-0634-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-015-0634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-015-0634-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T19:52:42Z","timestamp":1652817162000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-015-0634-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,8]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1186\/s13256-015-0634-4","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,8]]},"assertion":[{"value":"3 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"158"}}